The treatment of infections is becoming
more difficult due to emerging
resistance of pathogens to existing drugs. As such, alternative druggable
targets, particularly those that are essential for microbe viability
and thus make it harder to develop resistance, are desperately needed.
In turn, once identified, safe and effective agents that disrupt these
targets must be developed. Microbial acquisition and use of iron is
a promising novel target for antimicrobial drug development. In this
Review we look at the various facets of iron metabolism critical to
human infection with pathogenic microbes and the various ways in which
it can be targeted, altered, disrupted, and taken advantage of to
halt or eliminate microbial infections. Although a variety of agents
will be touched upon, the primary focus will be on the potential use
of one or more gallium complexes as a new class of antimicrobial agents. In vitro and in vivo data on the activity
of gallium complexes against a variety of pathogens including ESKAPE
pathogens, mycobacteria, emerging viruses, and fungi will be discussed
in detail, as well as pharmacokinetics, novel formulations and delivery
approaches, and early human clinical results.